You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤龍藥業(002864.SZ):一種抑制冠狀病毒3CL蛋白酶活性的3-三唑基甲基1,3,5-三嗪-2,4-二酮類化合物及其製備方法和應用獲得美國專利授權
格隆匯 04-03 20:06

格隆匯4月3日丨盤龍藥業(002864.SZ)公佈,近日,公司與陝西科技大學梁承遠教授團隊合作的“冠狀病毒3CL蛋白酶抑制劑開發”項目候選藥物PLC-01及其核心化合物獲得了美國專利授權。

PLC-01是一種抑制冠狀病毒3CL蛋白酶活性的3-三唑基甲基-1,3,5-三嗪-2,4-二酮類化合物,是國外已上市抗新冠藥物恩斯特韋(Xocova)的生物電子等排體。PLC-01能夠有效抑制SARS-CoV-2 3CLpro活性,阻斷SARS-CoV-2病毒在體內的複製和轉錄,具有優良的藥代動力學特徵和安全性,可單獨口服給藥,具有非常好的應用前景,為後期開發國內、國際市場打下基礎。目前公司正在全力推進PLC-01項目的非臨牀研究,實現中國和美國IND申報。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account